All articles tagged with #pompe disease
Maze Therapeutics CEO, Jason Coloma, expressed personal disappointment after learning that Sanofi terminated their partnership to develop an experimental drug for Pompe disease through a public statement, rather than direct communication. Sanofi cited disagreement with the U.S. Federal Trade Commission's decision to block the licensing deal but decided against legal action, stating it was not in the best interest of patients.
Sanofi expresses disappointment with the Federal Trade Commission's decision to seek a preliminary injunction against its proposed licensing agreement with Maze Therapeutics for the development of MZE001, a potential treatment for Pompe Disease. Sanofi disagrees with the action, stating that it would delay potential advancements and impact patients' lives. As a result, Sanofi has decided to terminate the agreement with Maze Therapeutics. The company remains committed to addressing the unmet needs of the Pompe patient community.
The Federal Trade Commission (FTC) is seeking to block Sanofi's acquisition of an exclusive license to Maze Therapeutics' therapy for Pompe disease, alleging that the deal would eliminate a potential competitor and protect Sanofi's monopoly in the market. Sanofi currently holds a monopoly on FDA-approved drugs for Pompe disease, charging high prices for treatment. Maze's developmental drug, MZE001, threatens to undermine this monopoly as the first oral medication for Pompe disease patients. The FTC argues that the acquisition would deprive patients of innovative and affordable treatment options, and is seeking a temporary restraining order and preliminary injunction to prevent the acquisition.